Maryland placed third on think tank Milken Institute’s 2018 State Technology and Science Index, ranking innovation pipelines. Maryland also placed third in 2016’s report.
The first Food and Drug Administration approvals for cell and gene therapies are already more than a year out, but 2019 is likely to be a significant year for the field, particularly in areas like international interest, industry consolidation and pricing. That was the theme of a panel discussion Monday morning at Biotech Showcase in San Francisco, which coincides with the 2019 J.P. Morgan Healthcare Conference.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
What are the top universities in the United States? The list is decided by the CEOWORLD magazine university ranking which considers 7 important factors to help make a balanced comparison. These include influence, reputation, specialization, recruiters Responses and employers Feedback, which in turn help to rate and rank the top unis.
In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry.
Now in its 37th year, the conference has ballooned from a small event with 150 attendees that was essentially the ” birth of biotech,” to an event attended by everyone from the biggest pharma company to the smallest biotech. JPMorgan said more than 485 companies are scheduled to present this year.
Personal Genome Diagnostics is starting off the year with news of a pair of partnership agreements as it looks to expand its approach to cancer testing.
Congratulations to Bahija on making MedImmune the leading BioHealth company in Maryland and accelerating its growth. Also many thanks for the MedImmune longtime support of BHI and helping the BioHealth Capital Region become the 4th largest Life Science region in the country.
Six years after AstraZeneca’s then new CEO Pascal Soriot named Bahija Jallal president of the big MedImmune subsidiary in Gaithersburg, MD, putting her at the center of the company’s R&D turnaround plans, the longtime pharma exec is joining the great migration of industry professionals to biotech.
Bristol-Myers Squibb Co.’s $74 billion planned purchase of Celgene Corp. puts it in line to lead the drug industry’s hottest market, cancer, as early as next year.
Many thanks to Dan for his leadership of Emergent, his service as a loyal BHI Board Member and for helping accelerate the growth of the BIO Health Capital Region
Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.